Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized ATG Dose in Haploidentical HSCT
NCT03190733Phase 4Unknown
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Aug 2017
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Chronic Graft-versus-host-disease at 1 year. Status: unknown.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03190733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190733.